[
    {
        "id": 4437,
        "drug_name": "CYRAMZA (ramucirumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hepatocellular Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-13",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-cyramzar-ramucirumab-becomes-first-fda-approved-biomarker",
        "note": "FDA approval announced May 13, 2019.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2796,
        "drug_name": "EYLEA (aflibercept)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Nonproliferative Diabetic Retinopathy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-13",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy",
        "note": "FDA Approval announced May 13, 2019.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5116,
        "drug_name": "BAVENCIO (avelumab) and INLYTA (axitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Renal cell carcinoma (RCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-14",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda_approves_bavencio_avelumab_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma",
        "note": "FDA Approval announced May 14, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5206,
        "drug_name": "VENCLEXTA (venetoclax) and GAZYVA (obinutuzumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Chronic Lymphocytic Leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-15",
        "link": "https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-announces-us-fda-approval-venclexta-venetoclax-as-chemotherapy-free-combination-regimen-for-previously-untreated-chronic-lymphocytic-leukemia-patients.htm?view_id=822",
        "note": "FDA approval announced May 15, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5206,
        "drug_name": "VENCLEXTA (venetoclax) and GAZYVA (obinutuzumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Chronic Lymphocytic Leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-15",
        "link": "https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-announces-us-fda-approval-venclexta-venetoclax-as-chemotherapy-free-combination-regimen-for-previously-untreated-chronic-lymphocytic-leukemia-patients.htm?view_id=822",
        "note": "FDA approval announced May 15, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4039,
        "drug_name": "JAKAFI (Ruxolitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Graft versus host disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-24",
        "link": "http:\/\/incyte.gcs-web.com\/news-releases\/news-release-details\/fda-approves-jakafir-ruxolitinib-treatment-patients-acute-graft",
        "note": "FDA approval announced May 24, 2019.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3386,
        "drug_name": "ZOLGENSMA (AVXS-101)",
        "clinical_trial_id": "NCT03306277",
        "has_trial_insight_page": 0,
        "indication": "Spinal muscular atrophy (SMA) Type 1",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-24",
        "link": "http:\/\/hugin.info\/134323\/R\/2244902\/886731.pdf",
        "note": "FDA Approval announced May 24, 2019.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2918,
        "drug_name": "REVLIMID - AUGMENT",
        "clinical_trial_id": "NCT01938001",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or Refractory Follicular Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-28",
        "link": "https:\/\/ir.celgene.com\/press-releases\/press-release-details\/2019\/FDA-Approves-REVLIMID-Lenalidomide-In-Combination-With-Rituximab-For-the-Treatment-of-Adult-Patients-with-Previously-Treated-Follicular-Lymphoma-or-Marginal-Zone-Lymphoma\/default.aspx",
        "note": "FDA Approval announced May 28, 2019.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5115,
        "drug_name": "ZERBAXA(ceftolozane and tazobactam)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hospital-acquired bacterial pneumonia (HABP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-03",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-Mercks-ZERBAXA-ceftolozane-and-tazobactam-3g-Dose-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP\/default.aspx",
        "note": "FDA approval announced June 3, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4658,
        "drug_name": "EMGALITY (galcanezumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cluster headache",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-04",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-emgalityr-galcanezumab-gnlm-first-and-only",
        "note": "FDA Approval announced June 4, 2019.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5264,
        "drug_name": "NUCALA (Mepolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Severe eosinophilic asthma - pediatric",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-06",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options\/",
        "note": "FDA Approval announced June 6, 2019.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5722,
        "drug_name": "EMFLAZA (deflazacort)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Duchenne muscular dystrophy (age 2-5)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-07",
        "link": "http:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-receives-fda-approval-expansion-emflazar",
        "note": "FDA Approval announced for label expansion June 7, 2019.",
        "company_entity_id": 251,
        "company_ticker": "PTCT",
        "company_name": "PTC Therapeutics Inc.",
        "company_price": "31.6900",
        "company_change": 0.99,
        "company_percent_change": 3.22,
        "company_optionable": 1,
        "company_number_of_shares": 76608030,
        "price_change_sparkline": [
            [
                26.09,
                1706677200
            ],
            [
                26.03,
                1706763600
            ],
            [
                25.18,
                1706850000
            ],
            [
                25.07,
                1707109200
            ],
            [
                26.79,
                1707195600
            ],
            [
                25.24,
                1707282000
            ],
            [
                25.25,
                1707368400
            ],
            [
                25.51,
                1707454800
            ],
            [
                25.92,
                1707714000
            ],
            [
                24.15,
                1707800400
            ],
            [
                25.04,
                1707886800
            ],
            [
                25.69,
                1707973200
            ],
            [
                25.91,
                1708059600
            ],
            [
                25.98,
                1708405200
            ],
            [
                25.94,
                1708491600
            ],
            [
                26.04,
                1708578000
            ],
            [
                27.07,
                1708664400
            ],
            [
                27.95,
                1708923600
            ],
            [
                28.31,
                1709010000
            ],
            [
                28.2,
                1709096400
            ],
            [
                28.19,
                1709182800
            ],
            [
                31.95,
                1709269200
            ],
            [
                30.98,
                1709528400
            ],
            [
                31.3,
                1709614800
            ],
            [
                30.88,
                1709701200
            ],
            [
                30.76,
                1709787600
            ],
            [
                31.16,
                1709874000
            ],
            [
                30.7,
                1710129600
            ],
            [
                31.69,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5507,
        "drug_name": "Polatuzumab vedotin and bendamustine plus RITUXAN (rituximab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Diffuse large B-cell lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-10",
        "link": "http:\/\/investor.seattlegenetics.com\/news-releases\/news-release-details\/seattle-genetics-antibody-drug-conjugate-technology-utilized",
        "note": "FDA approval announced June 10, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5507,
        "drug_name": "Polatuzumab vedotin and bendamustine plus RITUXAN (rituximab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Diffuse large B-cell lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-10",
        "link": "http:\/\/investor.seattlegenetics.com\/news-releases\/news-release-details\/seattle-genetics-antibody-drug-conjugate-technology-utilized",
        "note": "FDA approval announced June 10, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4986,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "NCT02358031",
        "has_trial_insight_page": 0,
        "indication": "Head and neck squamous cell carcinoma (HNSCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-11",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-Two-New-Indications-for-Mercks-KEYTRUDA-pembrolizumab\/default.aspx",
        "note": "FDA Approval announced June 11, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2996,
        "drug_name": "ABP 980 (Kanjinti; trastuzumab-anns)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Herceptin biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-13",
        "link": "http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2401433",
        "note": "FDA approval announced June 13, 2019.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3263,
        "drug_name": "DEXTENZA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Post-surgical ocular inflammation and pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-21",
        "link": "http:\/\/investors.ocutx.com\/news-releases\/news-release-details\/ocular-therapeutixtm-announces-fda-approval-supplemental-new",
        "note": "FDA Approval June 21, 2019.",
        "company_entity_id": 222,
        "company_ticker": "OCUL",
        "company_name": "Ocular Therapeutix Inc.",
        "company_price": "9.2900",
        "company_change": -0.43999999999999995,
        "company_percent_change": -4.52,
        "company_optionable": 1,
        "company_number_of_shares": 79418626,
        "price_change_sparkline": [
            [
                4.86,
                1706677200
            ],
            [
                5.25,
                1706763600
            ],
            [
                5.18,
                1706850000
            ],
            [
                4.95,
                1707109200
            ],
            [
                5.04,
                1707195600
            ],
            [
                5,
                1707282000
            ],
            [
                5.03,
                1707368400
            ],
            [
                5.68,
                1707454800
            ],
            [
                5.88,
                1707714000
            ],
            [
                5.62,
                1707800400
            ],
            [
                6.46,
                1707886800
            ],
            [
                6.86,
                1707973200
            ],
            [
                7.58,
                1708059600
            ],
            [
                7.52,
                1708405200
            ],
            [
                7.52,
                1708491600
            ],
            [
                9.7,
                1708578000
            ],
            [
                9.86,
                1708664400
            ],
            [
                9.9,
                1708923600
            ],
            [
                9.9,
                1709010000
            ],
            [
                9.95,
                1709096400
            ],
            [
                10.06,
                1709182800
            ],
            [
                10.75,
                1709269200
            ],
            [
                10.88,
                1709528400
            ],
            [
                10.93,
                1709614800
            ],
            [
                10.83,
                1709701200
            ],
            [
                10.37,
                1709787600
            ],
            [
                9.98,
                1709874000
            ],
            [
                9.73,
                1710129600
            ],
            [
                9.29,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3095,
        "drug_name": "SYMDEKO (tezacaftor\/ivacaftor and ivacaftor)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cystic fibrosis - Two Copies of the F508del Mutation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-21",
        "link": "https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/fda-approves-symdekor-tezacaftorivacaftor-and-ivacaftor-treat",
        "note": "Label expanded to now include all patients over 6 years old - June 21, 2019.",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5571,
        "drug_name": "BOTOX",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Upper limb spasticity",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-21",
        "link": "https:\/\/www.allergan.com\/News\/News\/Thomson-Reuters\/FDA-Approves-BOTOX-onabotulinumtoxinA-for-Pediatr",
        "note": "FDA Approval announced June 21, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2799,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "NCT02912468",
        "has_trial_insight_page": 0,
        "indication": "Nasal polyps",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-26",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-dupixentr-dupilumab-chronic-rhinosinusitis-nasal",
        "note": "FDA Approval announced June 26, 2019.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2799,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "NCT02912468",
        "has_trial_insight_page": 0,
        "indication": "Nasal polyps",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-26",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-dupixentr-dupilumab-chronic-rhinosinusitis-nasal",
        "note": "FDA Approval announced June 26, 2019.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3000,
        "drug_name": "SOLIRIS (Eculizumab)",
        "clinical_trial_id": "NCT01892345",
        "has_trial_insight_page": 0,
        "indication": "Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-27",
        "link": "https:\/\/ir.alexion.com\/news-releases\/news-release-details\/alexion-receives-fda-approval-solirisr-eculizumab-treatment",
        "note": "FDA Approval announced June 27, 2019.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5243,
        "drug_name": "THIOLA EC (tiopronin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cystinuria",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-28",
        "link": "http:\/\/ir.retrophin.com\/news-releases\/news-release-details\/retrophin-announces-fda-approval-thiolar-ec-tiopronin-100mg-and",
        "note": "FDA Approval announced June 28, 2019.",
        "company_entity_id": 850,
        "company_ticker": "TVTX",
        "company_name": "Travere Therapeutics Inc.",
        "company_price": "7.7500",
        "company_change": -0.24,
        "company_percent_change": -3,
        "company_optionable": 1,
        "company_number_of_shares": 76098485,
        "price_change_sparkline": [
            [
                8.93,
                1706677200
            ],
            [
                8.6,
                1706763600
            ],
            [
                8.49,
                1706850000
            ],
            [
                8.26,
                1707109200
            ],
            [
                8.67,
                1707195600
            ],
            [
                8.28,
                1707282000
            ],
            [
                8.3,
                1707368400
            ],
            [
                8.48,
                1707454800
            ],
            [
                8.86,
                1707714000
            ],
            [
                7.99,
                1707800400
            ],
            [
                8.25,
                1707886800
            ],
            [
                8.74,
                1707973200
            ],
            [
                8.2,
                1708059600
            ],
            [
                8.28,
                1708405200
            ],
            [
                7.88,
                1708491600
            ],
            [
                7.86,
                1708578000
            ],
            [
                7.94,
                1708664400
            ],
            [
                8.02,
                1708923600
            ],
            [
                8.31,
                1709010000
            ],
            [
                7.79,
                1709096400
            ],
            [
                7.56,
                1709182800
            ],
            [
                7.87,
                1709269200
            ],
            [
                8.19,
                1709528400
            ],
            [
                8.04,
                1709614800
            ],
            [
                8.61,
                1709701200
            ],
            [
                8.71,
                1709787600
            ],
            [
                8.66,
                1709874000
            ],
            [
                7.99,
                1710129600
            ],
            [
                7.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5908,
        "drug_name": "PF-06439535",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Biosimilar bevacizumab",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-28",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr",
        "note": "FDA Approval announced June 28, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    }
]